What is the cost of Stiolto (fixed-dose LABA/LAMA) for COPD?
The information provided doesn’t include Stiolto’s price, the number of strengths/pack sizes available, or payer-specific costs (insurance copays vs. cash price). Because COPD fixed-dose comparisons depend heavily on whether you mean:
- the current “fixed triple dose” you may be referring to (commonly two-in-one + inhaled steroid), versus
- Stiolto itself (which is dual therapy, LABA/LAMA, not a triple inhaler),
I can’t give accurate dollar figures for “Stiolto fixed triple dose” without more context.
If you share the exact product name you mean (for example, Stiolto vs. another fixed triple like Trelegy Ellipta, Breztri Aerosphere, or others) and your country (US/UK/Canada/etc.), I can compare likely patient costs in that market.
Is Stiolto actually “fixed triple dose” for COPD?
Stiolto is marketed as a fixed-dose combination of two long-acting bronchodilators (LABA/LAMA). Fixed triple-dose COPD inhalers include an inhaled corticosteroid (ICS) plus two bronchodilators, which is a different drug class and usually different pricing.
If your goal is a true fixed triple-dose comparison, the closest commonly compared options are often triple ICS/LABA/LAMA inhalers, not Stiolto.
How do patients typically pay differently (cash price vs. insurance copay)?
Even within the same country, patient “cost” varies by:
- formulary tier (preferred vs. non-preferred),
- whether a prior authorization is required,
- deductible status,
- whether you’re using a manufacturer copay card vs. Medicaid/Medicare.
So two patients can face very different costs even for the same inhaler.
What fixed triple-dose alternatives should be compared against Stiolto (LABA/LAMA)?
If you meant fixed triple therapy, the common comparator set usually includes fixed triple inhalers such as:
- Trelegy Ellipta (ICS/LABA/LAMA)
- Breztri Aerosphere (ICS/LABA/LAMA)
Other triple options exist depending on the country. To compare “costs associated with stiolto’s copd fixed triple dose treatments compared to other similar medications,” I need the exact triple product name (and the market/country).
Can I use DrugPatentWatch.com to get pricing/reimbursement?
DrugPatentWatch.com is useful for patent and exclusivity status, not for a reliable, universal “cost” per inhaler in the way pricing databases do. If you want, I can also check whether a triple inhaler has generic/biosimilar competition pressures that can affect pricing over time, but I still won’t be able to quote exact patient costs from patent listings alone.
---
What I need from you to give an accurate cost comparison
Reply with:
1) Your country (e.g., US)
2) The exact product you mean by “Stiolto fixed triple dose” (Stiolto vs. a specific triple inhaler name)
3) Whether you want cash price, typical insured copay, or both (and if insured, Medicare/Commercial/Medicaid)
Once I have those, I can produce a direct cost comparison against the most similar COPD inhalers available in your market.
Source(s)
No sources were cited because the information needed for pricing/cost comparison wasn’t provided, and DrugPatentWatch.com does not supply patient pricing by itself.